IN MATRICO™ Drug Discovery
Increasing predictiveness and confidence in drug discovery
for cancer, fibrosis, and other devastating diseases.
News
VIVIQ™ Skin Health Launches to Bring Clinical Benefits to Prestige Skincare
Xylyx Bio launched VIVIQ Skin Health, a prestige skincare brand with the world’s first and only skincare product powered by Matrikynes® biotechnology, a clinically proven blend of extracellular matrix peptides designed to bring clinic-worthy results to consumer skincare.
Read MoreXylyx Bio and Cell&Soft Announce positive initial results following Strategic Partnership to Develop Next-Generation in vitro Platforms to Accelerate Cancer Drug Discovery
New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology.
Read MoreXYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery
Xylyx Bio now offers specialized contract R&D services based on its highly predictive IN MATRICO™ platform. Xylyx Bio’s custom assays incorporate human disease-specific extracellular matrix (ECM) substrates combined with clinically relevant informatics to better represent human biology and reliably de-risk drug discovery through early efficacy signals that simultaneously reduce costs and development time.
Read MoreXYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery
Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH.
Read MoreVIVIQ™ Skin Health Launches to Bring Clinical Benefits to Prestige Skincare
Xylyx Bio launched VIVIQ Skin Health, a prestige skincare brand with the world’s first and only skincare product powered by Matrikynes® biotechnology, a clinically proven blend of extracellular matrix peptides designed to bring clinic-worthy results to consumer skincare.
Read MoreXylyx Bio and Cell&Soft Announce positive initial results following Strategic Partnership to Develop Next-Generation in vitro Platforms to Accelerate Cancer Drug Discovery
New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology.
Read MoreXYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery
Xylyx Bio now offers specialized contract R&D services based on its highly predictive IN MATRICO™ platform. Xylyx Bio’s custom assays incorporate human disease-specific extracellular matrix (ECM) substrates combined with clinically relevant informatics to better represent human biology and reliably de-risk drug discovery through early efficacy signals that simultaneously reduce costs and development time.
Read MoreXYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery
Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH.
Read MoreXylyx Bio and Cell&Soft Announce Strategic Partnership to Develop Next-Generation Cell Culture Platforms to Accelerate Cancer Drug Discovery
New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates,today announced a strategic partnership for the development of in vitro cellular models for cell-based assays in oncology.
Read MoreWebinar: Transforming lung fibrosis drug discovery with the IN MATRICO® Human Lung Fibrosis platform
Lung extracellular matrix (ECM) is implicated in the pathogenesis and progression of lung fibrosis. Current preclinical lung fibrosis models do not incorporate lung ECM, and therefore lack the defining part of the fibrotic lung disease environment. In this webinar, we describe the paradigm shift in drug discovery from ‘in vitro’ to ‘in matrico’, and present […]
Read MoreWebinar: Redefining cancer research with IN SITE™ Metastasis Kit
Metastasis is the dissemination of cancer cells to distant organs: bone, liver, and lung being the most common sites of metastasis. The lack of in-vitro models that recapitulate the tissue-specific extracellular matrix (ECM) in metastatic sites presents a significant barrier for better understanding the mechanisms driving tumor colonization and consequently to developing drugs that effectively […]
Read MoreXylyx Bio releases advanced disease model system to improve cancer drug discovery
More faithful representation of disease biology is key to identify drivers of metastasis and targets for therapeutic intervention. Xylyx Bio’s IN SITE™ Metastasis Kit incorporates native tissue bone, liver, and lung extracellular matrices to provide key features of site-specific microenvironments, allowing scientists to more accurately model cancer metastasis in common secondary sites.
Read More
Previous
Next
